Immunomet Therapeutics
Health Care · Oncology Therapeutics
Overview
ImmunoMet Therapeutics is a clinical-stage oncology company developing lixumistat (IM156), a best-in-class OxPhos inhibitor targeting the metabolic dependency that drives cancer-cell survival in resistant tumours.
Funding and backers
Total raised
$842k
1 round on record
Latest round
$842k
Venture round · Jan 2026 · 9 mo ago
Team
51-200
employees, estimated range
The money's age
Fresh money
9 months since the last round · not hiring
Momentum
20/100
fresh money
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jan 2026 | $842k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Immunomet Therapeutics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Dean WelschExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
backs Alterome, Avenzo Therapeutics
backs Avenzo Therapeutics
backs Alterome
backs Lyell
backs Avenzo Therapeutics
Similar startupsby what they do, their industry and backers
Alterome is a clinical-stage precision oncology company developing first-in-class, alteration-specific therapies for AKT E17K- and…
CasInvent Pharma | CasInvent Pharma. Fighting resistant tumors with best-in-class inhibitors of casein kinase 1 (CK1).
Cairn Therapeutics: Targeting the Cancer, just the cancer. Making cancer treatment simpler and safer with CT-262.
Eisbach Bio is a clinical-stage biotechnology company developing next-generation cancer therapies with its proprietary ALLOS platform.
Mission / Vision a new approach to treat blood cancers Reprogramming leukemic cells in vivo Modiblast is a privately held biopharmaceutical…
Avenzo Therapeutics is a clinical-stage biotechnology company that develops next-generation targeted oncology therapies. It was co-founded…
Financials
Total raised
$842k
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2026 | $842k | Details |
People
Dean Welsch
Executive Officer, Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Houston
United States
HQ
50-200 est. staff